RSV Awareness Online Tool

The aim of the RSV Awareness online tool is to track global public awareness of Respiratory Syncytial Virus (RSV) by utilizing online search volumes.

News updates

Registration for RSVVW’24 is open!

​On 13-16 February, 2024, we will host our 8th conference RSVVW’24 – A Global Conference on Novel RSV Preventive and Therapeutic Interventions. We are looking forward to welcoming you at our in-person conference in Mumbai, India.

Find more information about RSVVW’24 on the conference homepage!

Webinar Recording Available: “RSV and Asthma”

Our latest ReSViNET Webinar was held on the 6th of September with Prof Tina Hartert, MD, MPH, as our guest speaker. She shared her insights on RSV in relationship to asthma. Her study of almost two thousand children has identified that delay in early life respiratory syncytial virus (RSV) decreases the risk of developing childhood asthma. These findings underscore the role of RSV in both acute and chronic respiratory disease and pave the way for asthma prevention efforts.


A father-daughter team is working to reduce child mortality in Bangladesh.

As a little girl growing up in Bangladesh, Senjuti Saha remembers how dinner conversations in her family often focused on bacteria, viruses, and infectious diseases.

Those topics might strike many people as a little gross at mealtime, but in the Saha family that’s what happened when her father, Dr. Samir Saha, brought his work home. A professor of microbiology, Samir used family dinner to practice his scientific lectures or share what he was learning about Bangladesh’s health challenges. 

Paper of the Month: August 2023

Respiratory syncytial virus infection and novel interventions

Authors: Annefleur C. Langedijk & Louis J. Bont

The large global burden of respiratory syncytial virus (RSV) respiratory
tract infections in young children and older adults has gained
increased recognition in recent years. Recent discoveries regarding
the neutralization-specifc viral epitopes of the pre-fusion RSV
glycoprotein have led to a shift from empirical to structure-based design
of RSV therapeutics, and controlled human infection model studies
have provided early-stage proof of concept for novel RSV monoclonal
antibodies, vaccines and antiviral drugs.

RSV Dashboard 

We are proud to announce we have developed the first-ever global RSV surveillance dashboard and it is now live!

ReSViNET Foundation, in collaboration with AstraZeneca, is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally. This will include at least 20 countries that are representative of different geographic regions from both hemispheres.

Connecting research and society

The ReSViNET Foundation is the first and leading global non-profit organisation fully committed to reducing the global burden of the Respiratory Syncytial Virus (RSV).

We collaborate with researchers, the health sector, governments, international statutory bodies, non-profit organisations and the wider civil society in an effort to coordinate actions and raise awareness about RSV infection and to tackle the challenge of RSV infection prevention and treatment.

A global health challenge

Every year, Respiratory Syncytial Virus (RSV) affects more than 33 million children under 5 years worldwide. It is one of our most significant global healthcare challenges, not only in infants, but also in older adults. ReSViNET is the first official RSV foundation and aims to provide a platform for global collaborations to raise awareness about RSV infection and stimulate the development of RSV prevention and treatment.